confirmed by immunofluorescent labeling and analysis by immunofluorescence flow cytometry.
Materials and Methods
Experimental Animals. Adult female mice of strains C57BL/6, CBA/J, DBA/2, and C57BL/ 6 X DBA/2 Fa (BDFI) were obtained from The Jackson Laboratory, Bar Harbor, ME, or Laboratory Supply Co., Indianapolis, IN. Adult mice from strains B10.D2 and B10.A(5R)/Sgn were obtained as the progeny of breeding pairs obtained from The Jackson Laboratory and maintained at the University of Chicago.
Cloned T Lymphocytes. CTL clones L3 and BI8 are ofC57BL/6 anti-DBA/2 origin (12) . L3 specifically lyses target cells that express surface antigens controlled by genes located in the right half of the H-2 d haplotype of the major histocompatibility complex (MHC) (5) . B18 is specific for target cells expressing antigens controlled by the left half of the MHC, probably H-2K d (5) . The CTL clones T18 and T38 were derived from primary C57BL/10 (B10) anti-TNP-B10 MLC (13) . Clone T18 specifically ggses TNP-modified target cells expressing H-2D ~ antigen. Clone T38 specifically lyses TNP-modified cells that bear H-2D b'd's antigens. The CTL clones L3, B18, T18, and T38 express Lyt-2)2 antigen on their surface.
The maintenance of the CTL clones L3 and B 18 has been described previously (3) . Briefly, L3 and B18 cells were maintained by weekly restimulation with irradiated alloantigen and secondary MLC supernatant in Dulbecco's modified Eagle's medium (DME) (H-21; Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) containing 2% fetal calf serum (FCS) (KC Biological, Inc., Lenexa, KS), 100 U/ml penicillin, 100 #g/ml streptomycin, and additional (14) amino acids. Each well (Linbro 24-well plate, 76-033-05; Linbro Chemical Co., Hamden, CT) contained 2 × 104 L3 or B18 cells, 6.5 × l0 s irradiated (1,400 rad) (model 143 cesium irradiator: JLS Shepherd & Associates, Glendale, CA) DBA/2 spleen cells, and 33% supernatant from secondary MLC in'a final volume of 1.6 ml. Culture plates were then incubated in a 37°C 5% COz humidified incubator.
Antibodies. Monoclonal antibodies 2.43 (anti-Lyt-2.2), 3.155 (anti-Lyt-2), 15E (anti-Thy-1.2), and 83A (anti-Thy-l.2) have been described (10, 15) . Fluorescein isothiocyanate-coupled rabbit anti-mouse immunoglobulin (Ig) produced by one of the authors (M. Loken) has been described previously (16) .
Immunization Procedure. BDFI mice were immunized five times, with each injection consisting of ~2 X i0 T cloned L3 CTL cells. The first injection was given intraperitonealIy in complete Freund's adjuvant followed at 3-wk intervals by intraperitoneat injections in incomplete Freund's adjuvant. Inhibitory effects on cytolysis of P-815 (H-2 't) target cells by L3 cloned CTL could be detected in the serum of animals after the fourth injection. 3 d before fusion, a final intraveneous injection of L3 cells was given.
Fusion. Spleen cells from immune BDF~ mice were fused with SP2/0-Agl4 (SP2/0) hybrid cells using the polyethylene glycol fusion procedure described by McKearn et al. (17) .
Assays for Inhibition of Cytolysis. Microinhibition assays for the screening and analysis of hybridoma supernatants were performed using the method of Dialynas et al. (11) . Briefly, the effector cells were incubated with antibody for 30 min at 4°C, followed by the addition of'~lCr -labeled target cells and incubation at 37°C for periods ranging from 30 to 90 min to induce the lyric injury. EDTA was then added to prevent further lysis, and cells were incubated for an additional period of 2 3 h to permit maximum release of 51Cr. The effector/target cell ratio and incubation times were predetermined for each cloned CTL to provide the maximum sensitivity for detection of inhibition of cytolysis.
Inhibition of cytolysis of several cloned CTL and of primary MLC cells was determined over a range of effector/target cell ratios using a short-term SlCr-release assay described previously (10) . This procedure was modified to test for inhibition of cytolysis under lectin-facilitated conditions by increasing the period of incubation before the addition of EDTA to provide for optimal specific 5~Cr release from the targets.
Fluorescence Staining and Flow @tofluorometric Analysis. Indirect immunofluorescence was used in all instances. Cloned CTL, normal tissue cells,,or 5 d MLC cells were centrifuged over a Ficoll-Hypaque gradient (18) , washed thoroughly in medium and distributed for fluorescence staining. A two-stage technique was used with staining at room temperature in the presence of 0.2% sodium azide. The first-step antibody was incubated under saturating conditions with 106 cells for 15 min in 25 #1 total volume. Cells were washed by the addition of 75 #1 Dulbecco's phosphate-buffered saline (DPBS) containing 5% agammaglobulinemic horse serum (AGH) over a cushion of 25 #1 AGH, and centrifuged at 600 g for 15 rain. The second step reagent was fluorescein-coupled rabbit anti-mouse Ig that was added under saturating conditions in a final volume of 25 #1, and the cells were incubated and washed as described above. The stained cells were resuspended to a volume of 500 #1 in DPBS/5% AGH in the presence of propidium iodide (1.5 #g/ml) (19) .
Cells were analyzed using a fluorescence-activated cell sorter (FACS IV, B-D FACS Systems, Becton, Dickinson & Co., Sunnyvale, CA) equipped with a four decade logarithmic amplifier (Nozaki Associates, Inc., Palo Alto, CA). In all experiments, 104 viable ceils, as determined by exclusion of propidium iodide, were analyzed (19) .
Results obtained with experimental and control cell populations are presented as fluorescence histograms, with the number of cells on the y axis and the log of fluorescence intensity in arbitrary units on the x axis.
Trypsin Treatment of L3 Cells. Cloned L3 cells were harvested 6-7 d after the previous transfer, washed once in medium, and centrifuged over a 4-ml Ficoll-Hypaque gradient (18) . Cells recovered from the interface were washed three times in medium and once in serum-free DME. Cells were resuspended in Hanks' balanced salt solution (without Ca ++ or Mg ++) at a concentration of 2 X 107 cells/ml. An equal volume of trypsin (Miles Laboratories Inc., Research Products Div., Elkhart, IN) at various concentrations was added to the cell suspension, and the mixture was incubated at 37°C for 30 rain. Ice-cold DME (10 ml) with 20% FCS was added to stop the reaction. The cells were washed three times in cold medium and counted. Overnight incubation of trypsin-treated cells was performed by culturing approximately 5 × 106 L3 cells in 1 ml of medium in a plastic culture plate (76-033-05; Linbro Chemical Co.) The incubation was continued for 18 h at 37°C in a humidified 5% COz atmosphere.
Mixed Lymphocyte Cultures. Primary 5-d MLC cells were prepared as described previously (14) . C57BL/6 responding cells (25 × 106) and irradiated (1,400 rad) stimulating cells (25 × 10 e') from various strains were combined in a final volume of 20 ml in plastic culture flasks (3024; Falcon Labware, Oxnard, CA). Cultures were allowed to incubate in a humidified 37°C incubator with a 5% COz atmosphere for 5 d.
Secondary MLC cells were generated from 12 14 d primary MLC by restimulating 3.5 × 106 primary MLC cells with 25 X 106 irradiated stimulating spleen cells from the appropriate strain. Responding cells were harvested for cytofluorometric analysis at 96 h following restimulation. Alternatively, 48 h after restimulation MLC cells were cloned as described (3) by limit dilution culture.
Results
Fusion Results. Sera from two mice which had been immunized with the L3 CTL clone cells (as described in Materials and Methods) were found to inhibit the lysis of the P-815 target cells by L3 but not by B 18 cells. Spleen cells from each of these mice were fused in separate fusions with myeloma cells, and the resulting hybrid cells were screened for clone-specific inhibition of cytolysis. The efficiency for the first fusion (microwells with growing cells per total microwells) was ~85% (816/960). The efficiency for the second fusion was ~82% (1,180/1,440). Two microwells from the first fusion and one microwell from the second fusion produced supernatants that inhibited the cytolysis of P-815 target cells by L3 but not B18 cells. One established hybridoma (designated FP384) was obtained from a microwell derived from the first fusion. This hybridoma was recloned, and the supernatants of that recloned line (designated 384.5) were used in the studies described below. Monoclonal antibody 384.5 is IgG3 (data not shown).
The Clone-specific Nature of the Inhibition of Cytolysis by Monoclonal Antibody 384.5. To examine the specificity of 384.5 blocking activity, CTL clones having distinct allo-or modified-self-reactivity were tested in antigen-mediated cytolytic assays in the presence or absence of antibody 384.5. Fig. 1 shows the characteristic inhibition profiles of 384,5 monoclonal antibody on the antigen-mediated lysis of P815 target cells by the CTL clones L3 and B18, in the microinhibition assay (9) . The cytolytic activity of CTL clone L3 (specific for H-2L a, unpublished data) was inhibited in the presence of 384.5 antibody over a range of antibody concentrations, but the cytolytic activity of another CTL clone B 18 (specific for H-2K d) was unaffected over the same range of antibody concentrations. In contrast, a potent anti-Lyt-2 monoclonal antibody, 3.155, blocked both L3 and B18 antigen-mediated lysis in a manner consistent with previously reported inhibition studies (9) . The effects of an irrelevant monoclonal antibody (anti-Thy-l.2), 83A, are also shown for comparison in Fig. 1 . The selective inhibition of L3 lytic activity by antibody 384.5 was tested over a range of effector to target cell ratios by using several cloned cytolytic T cell lines, including B18, T18 (which has cytolytic specificity for TNP-modified self [H-2b]-antigen), and T38 (a CTL line which reacts against TNP-modified self [H-2b]-or TNP-modified alloanti- (12) . The results shown in Table I indicate that the monoclonal antibody 384.5 inhibited cytolytic activity of the CTL clone L3 over a range of effector/target cell ratios. Antibody 384.5 failed to block TNP-specific H-2D a regionrestricted lysis of TNP-modified P815 target cells by the CTL clone T38 or the lysis of TNP-modified EL-4 target ceils by the CTL clone T18 (Table I ). In contrast, the nonpolymorphic anti-Lyt-2 antibody, 3.155, strongly inhibited L3, T38, and T18 cytolytic activities against their appropriate targets. We have now tested >90 shortterm cytolytic clones derived from alloreactive MLC that were not inhibited by the antibody 384. Antigen-specific cytolytic T lymphocytes can be induced in the presence of the lectins, concanavalin A (Con A) or phytohemagglutinin (PHA), to lyse inappropriate target cells (23) by a mechanism similar to antigen-mediated cytolysis (24) . CTL clones L3 and B18 were tested in lectin-facilitated ~aCr-release assays for their ability to lyse either syngeneic target cells, EL-4, or irrelevant allogeneic target cells, AKR-A, in the presence of antibody 384.5, an anti-Lyt-2.2 antibody (2.43), or medium. The data shown in Table III indicate that antibody 384.5 strongly inhibited Con Afacilitated cytolysis of both EL-4 and AKR-A target cells by the CTL clone L3. Interestingly, antibody 384.5 did not strongly inhibit PHA-facilitated cytolysis of AKR-A target cells by the L3 effector cells. We have also tested the specificity of inhibition of lectin-facilitated lysis by antibody 384.5. The data presented in Table  III show that antibody 384.5 did not inhibit Con A-facilitated cytolysis of EL-4 or T CELL CLONE-SF'ECIFIC MONOCLONAL ANTIBODY Incubations were continued at 37°C for 90 min in the presence of 20 gg/ml Con A or 2 gg/ml PHA before the addition of EDTA. Incubations were continued for a total of 180 min. The results are expressed as the percent specific lysis at the indicated effector/target cell rzitios.
antibody 384.5 was found to superimpose that of the second antibody (Fig. 2 B) . These findings indicate that the antigenic determinant detected by antibody 384.5 is present on L3 cells but not on B18 cells. We have found no evidence of specific binding of antibody 384.5 to 11 other cytolytic or amplifier T cell clones or to the P-815 target cells (data not shown). Normal tissues, including preparations of spleen, lymph node, thymus, and bone marrow cells from C57BL/6 and BDFa mice were tested for expression of the 384. The effect of trypsin proteolysis on L3 cell cytolytic activity was also determined with the same cell preparations used for the analysis of enzyme susceptibility of the 384.5 determinant. The effect of trypsin treatment on the capacity of the cloned L3 cells to lyse P-815 target cells is shown in Fig. 5 . The results indicate that the cytolytic efficiency of L3 cells decreased as a function of the increasing trypsin concentration. L3 cells treated with 1,000 /*g/ml of trypsin and incubated overnight in medium recovered their cytolytic potential.
Discussion
Our approach in this study was designed to obtain monoclonal antibodies capable of inhibiting cytolytic activity of cloned CTL in a clone-specific manner, We have used the CTL clone L3 to immunize F1 animals by using a procedure similar to that reported by Binz and Wigzell (6) to produce "antiidiotypic" antisera. The choice of an F1 hybrid mouse, a cross between the strain of origin of the effector cell and the strain of origin of the target cell, should favor the development of clone-specific antibodies. This situation minimizes the opportunity for production of antibodies reactive with Lyt-2, 170/100, MHC, and other antigens shared by the CTL clone and the mouse being immunized. It also lessens the chance for production of antibodies having specificity for target cell antigens which might be adsorbed to the cloned CTL used in the immunization (25) .
The antigen-mediated cytolytic process of CTL has been resolved into at least three steps (26): recognition-adhesion, the delivery of the lethal hit, and target cell distruction. Recognition-adhesion may represent two separate steps, but they have not been functionally resolved. Recognition of antigen is an essential element of the antigenmediated cytolytic process, and antibodies directed against the recognition structures on the CTL cell surface might be expected to interfere with that process. In the present study, we used a microinhibition screening procedure that was developed in this laboratory to provide a sensitive means of detecting monoclonal antibodies reactive with cell surface structures associated with the cytolytic process (11) . By combining the F1 immunization procedure and the functional screening assay, we identified the monoclonal antibody 384.5 that inhibits the cytolysis by the CTL clone L3 but does not inhibit cytolysis by other CTL clones. We have now tested the specificity of inhibition of cytolysis by antibody 384.5 with >90 short-term cytolytic clones derived from C57BL/6 anti-B10.A(5R) MLC; none of these clones were inhibited by the antibody 384.5.
The specificity of inhibition of cytolysis by antibody 384.5 correlated well with the specificity of antibody binding as determined by flow cytofluorometry. The determinant detected by antibody 384.5 is expressed by the L3 CTL clone, but not by 12 other cytolytic or amplifier T lymphocyte long-term clones, nor was it expressed on a detectable portion of cells derived from normal tissues or alloreactive primary MLC of C57BL/6 origin.
The clone-specific nature of the reactivity of antibody 384.5 distinguishes this antibody from other monoclonal antibodies derived in our laboratory such as antiLyt-2, anti-170/100, or anti-H-2 antibodies that inhibit lytic activity of CTL clones nonspecifically (9) . Furthermore, our cytofluorometry data suggest that the determinant detected by antibody 384.5 is expressed at a cell surface density much lower than that of the Lyt-2 molecular complex. Although the determinant detected by antibody 384.5 is distinct from those detected by the other antibodies that inhibit cytolysis, the nature of the molecule recognized by antibody 384.5 remains to be determined. It has not been possible thus far to obtain immunoprecipitates with antibody 384.5. This difficulty may relate to the low level of expression of the determinant with which this antibody reacts.
Our results indicate that the determinant detected by antibody 384.5 is removed by proteolytic digestion. Recent studies in this laboratory have shown that antigenic structures, including molecules bearing class I and class II determinants, can be adsorbed to the surface of cloned cytolytic and amplifier T lymphocytes (25) . The determinant detected by antibody 384.5 does not appear to be acquired in this way. The capacity of enzymatically treated L3 cells to reexpress the 384.5 determinant after overnight incubation indicates that the cell surface molecule bearing this determinant is endogenously synthesized by the L3 cells.
There are several potential mechanisms by which the antibody 384.5 may inhibit L3 cell cytolytic activity. The results of the binding studies suggest that the antibody inhibits cytolysis by binding specifically to the L3 effector cell and not to the target cell. Furthermore, these studies suggest that inhibition is probably not due to nonspecific "blanketing" effects from high antigen density, because the cytofluorometry studies indicate a relatively low antigen density on the surface of L3 cells. Antibody 384.5 is not directly cytotoxic to L3 cells, nor does it appear to induce effector cell autolysis under the conditions of the blocking assay as determined by 51Cr-release assays or trypan blue exclusion assays (unpublished data). Antibody 384.5 does not appear to inhibit cytolysis by binding directly to the molecule that delivers the lethal hit because this antibody specifically inhibits L3 cytolytic activity but not the cytolytic activity of other CTL clones. Furthermore, antibody 384.5 did not strongly inhibit PHA-facilitated cytolysis of AKR-A target cells by L3 effector cells. The results of preliminary studies on the effects of antibody 384.5 on antigen-specific conjugate formation between L3 cells and P-815 target cells suggest that this antibody inhibits L3 cell lysis of P-815 target cells by interfering with the recognition-adhesion step of the cytolytic process.
If the molecule bearing the determinant recognized by antibody 384.5 is involved in antigen recognition, then enzymatic removal or alteration of that molecule might be expected to result in the loss of antigen-mediated cytolytic activity. The simultaneous loss by L3 cells of antigen-specific cytolytic activity and the expression of the antigenic determinant detected by antibody 384.5 suggest that both properties have similar sensitivities to trypsin treatment. Results obtained in experiments that compare the susceptibility of L3 cell antigen-mediated cytolysis and lectin (Con A)-facilitated cytolysis to trypsin treatment (unpublished data) suggest that the L3 CTL clone antigen-mediated and lectin-facilitated cytolytic activities also have similar sensitivities to trypsin treatment. Berke et al. (27) have suggested that the CTL antigen receptor may play a role in cell-to-cell interactions that occur in lectin-facilitated lysis of irrelevant target cells. If this is true, and if antibody 384.5 reacts with a determinant on the T cell receptor, the ability of antibody 384.5 to inhibit both antigen-mediated and Con A-facilitated lysis is to be expected.
The monoclonal antibody 384.5 represents a reasonable candidate for an antibody directed against a determinant on the CTL receptor. This antibody binds specifically to and inhibits cytolysis by the CTL clone L3 but does not bind to or inhibit several other CTL clones. If antibody 384.5 recognizes an idiotypic determinant on the L3 cell antigen receptor, this idiotype does not appear to be dominant among the C57BL/6 T cell clonotypes that respond to H-2 e haplotype stimulation. Cells from primary 5-d MLC which react with antibody 384.5 have not been detected with certainty using flow cytofluorometric analysis (data not shown). However, when the cell populations are derived from MLC that were genetically "enriched" for cells reactive with determinants controlled by the H-2D d region [C57BL/6 anti-B 10.A(5R)] a small portion of these cells have been regularly observed to stain with antibody 384.5. It is possible that these cells represent a clonally expanded subpopulation that share an idiotypic determinant with the L3 CTL clone.
Antisera that appear to have antiidiotypic antibodies reactive with hapten-specific (7) or viral-specific (8) CTL have been produced by immunizing syngeneic mice with MLC cells that have cytolytic activity. Specificity for the appropriate CTL cells was suggested in these studies by the ability of these antisera to reduce cytolytic activity in the appropriate MLC cell preparations by treatment with antiserum and complement (7, 8) . However, none of these antisera inhibited cytolytic activity in the absence of complement (8) . Recently, antiidiotypic antisera have been produced by immunizing F1 mice with cloned alloreactive noncytolytic T cells (28) . Although these antisera stimulated clone-specific proliferation, they appear also to contain antibodies which bind to irrelevant clones as well as the specific clone (C. G. Fathman, personal communication).
The clone-specific nature of the reactivity exhibited by the monoclonal antibody 384.5 for a cytolytic T cell appears to be unique. This clone-specific reactivity of antibody 384.5 was demonstrated both in its capacity to inhibit L3 cytolysis and in its ability to bind to L3. The specific pattern suggests that this antibody may be reacting with the antigen-binding region of the antigen receptor on L3 CTL.
Summary
Monoclonal antibody 384.5 specifically inhibited cytolysis of P-815 target cells by cloned L3 cytotoxic T lymphocyte (CTL) effector ceils. The lytic activity of other cloned CTL that have other distinct specificities was not affected. Antibody 384.5 did not inhibit the cytolytic activity of bulk populations of C57BL/6 mixed lymphocyte culture (MLC) cells. Concanavalin A-facilitated cytolysis by T cell clone L3 but not T cell clone BI8 was inhibited by antibody 384.5, whereas phytohemagglutininfacilitated cytolysis by L3 cells was not strongly inhibited. Antibody 384.5 binds specifically to L3 cells but not to several other T lymphocytes clones, or to a detectable portion of populations of primary MLC cells, normal spleen, thymus, lymph node, or bone marrow cells. In contrast, C57BL/6 anti-B10.A(5R) secondary MLC cells (genetically enriched for reactivity against the H-2D d region gene products) contained a small population which reacted with the antibody 384.5. The determinant detected by antibody 384.5 was susceptible to trypsin treatment, and was reexpressed after overnight incubation. These results suggest that the monoclonal antibody 384.5 detects an endogenously synthesized clone-specific determinant associated with the cytolytic activity of the L3 CTL clone. These properties make antibody 384.5 an attractive candidate for an antibody that reacts with the antigen-recognition site of a cytolytic T cell antigen receptor.
